, and the 36-month beta value for AUTL is at 1.59. Analysts have varying views on the stock, with 8 analysts rating it as a “buy,” 0 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The average price suggested by analysts for AUTL is $6.97, which is $5.77 above the current market price. The public float for AUTL is 158.45M, and currently, shorts hold a 0.76% of that float. The average trading volume for AUTL on March 29, 2023 was 558.47K shares.
AUTL) stock’s latest price update
Autolus Therapeutics plc (NASDAQ: AUTL)’s stock price has decreased by -5.41 compared to its previous closing price of 1.85. However, the company has seen a -15.46% decrease in its stock price over the last five trading sessions. The Wall Street Journal reported on 11/07/21 that Blackstone to Invest in Autolus Therapeutics
AUTL’s Market Performance
AUTL’s stock has fallen by -15.46% in the past week, with a monthly drop of -9.33% and a quarterly drop of -6.17%. The volatility ratio for the week is 9.15% while the volatility levels for the last 30 days are 6.35% for Autolus Therapeutics plc The simple moving average for the last 20 days is -10.81% for AUTL stock, with a simple moving average of -30.03% for the last 200 days.
Analysts’ Opinion of AUTL
Many brokerage firms have already submitted their reports for AUTL stocks, with Wells Fargo repeating the rating for AUTL by listing it as a “Overweight.” The predicted price for AUTL in the upcoming period, according to Wells Fargo is $8 based on the research report published on March 27th of the current year 2023.
Bryan Garnier, on the other hand, stated in their research note that they expect to see AUTL reach a price target of $5. The rating they have provided for AUTL stocks is “Buy” according to the report published on March 17th, 2023.
Jefferies gave a rating of “Buy” to AUTL, setting the target price at $12 in the report published on June 14th of the previous year.
AUTL Trading at -11.79% from the 50-Day Moving Average
After a stumble in the market that brought AUTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.00% of loss for the given period.
Volatility was left at 6.35%, however, over the last 30 days, the volatility rate increased by 9.15%, as shares sank -9.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.67% lower at present.
During the last 5 trading sessions, AUTL fell by -15.46%, which changed the moving average for the period of 200-days by -37.05% in comparison to the 20-day moving average, which settled at $1.9525. In addition, Autolus Therapeutics plc saw -7.89% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for AUTL
Current profitability levels for the company are sitting at:
- -2707.41 for the present operating margin
The net margin for Autolus Therapeutics plc stands at -2402.95. The total capital return value is set at -51.03, while invested capital returns managed to touch -45.96. Equity return is now at value -63.00, with -41.60 for asset returns.
Based on Autolus Therapeutics plc (AUTL), the company’s capital structure generated 8.12 points at debt to equity in total, while total debt to capital is 7.51. Total debt to assets is 4.95, with long-term debt to equity ratio resting at 6.43. Finally, the long-term debt to capital ratio is 5.95.
When we switch over and look at the enterprise to sales, we see a ratio of -6.19, with the company’s debt to enterprise value settled at -0.14. The receivables turnover for the company is 0.22 and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.15.
Conclusion
In conclusion, Autolus Therapeutics plc (AUTL) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.